XOMA Corporation (XOMA): Price and Financial Metrics

XOMA Corporation (XOMA): $24.49

-0.30 (-1.21%)

POWR Rating

Component Grades













Add XOMA to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • Value is the dimension where XOMA ranks best; there it ranks ahead of 78.78% of US stocks.
  • The strongest trend for XOMA is in Value, which has been heading up over the past 48 weeks.
  • XOMA's current lowest rank is in the Growth metric (where it is better than 9.48% of US stocks).

XOMA Stock Summary

  • For XOMA, its debt to operating expenses ratio is greater than that reported by just 6.36% of US equities we're observing.
  • With a year-over-year growth in debt of -98.99%, XOMA Corp's debt growth rate surpasses just 1.6% of about US stocks.
  • As for revenue growth, note that XOMA's revenue has grown 179.47% over the past 12 months; that beats the revenue growth of 96.11% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to XOMA Corp, a group of peers worth examining would be CRTD, BEEM, PLAG, FNV, and FSM.
  • XOMA's SEC filings can be seen here. And to visit XOMA Corp's official web site, go to www.xoma.com.

XOMA Valuation Summary

  • XOMA's price/sales ratio is 12; this is 215.79% higher than that of the median Healthcare stock.
  • Over the past 243 months, XOMA's price/sales ratio has gone down 69.
  • XOMA's price/sales ratio has moved down 69 over the prior 243 months.

Below are key valuation metrics over time for XOMA.

Stock Date P/S P/B P/E EV/EBIT
XOMA 2021-08-31 12.0 3.0 34.7 20.3
XOMA 2021-08-30 12.1 3.1 35.0 20.5
XOMA 2021-08-27 11.2 2.8 32.4 18.6
XOMA 2021-08-26 11.2 2.8 32.4 18.5
XOMA 2021-08-25 11.0 2.8 31.9 18.2
XOMA 2021-08-24 11.0 2.8 31.8 18.1

XOMA Growth Metrics

  • The 4 year net income to common stockholders growth rate now stands at -42.35%.
  • Its year over year price growth rate is now at 31.07%.
  • Its 3 year revenue growth rate is now at -77.15%.
XOMA's revenue has moved up $20,443,000 over the prior 33 months.

The table below shows XOMA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 29.414 10.353 10.156
2021-03-31 28.957 11.458 10.153
2020-12-31 29.385 10.092 13.298
2020-09-30 2.227 -11.734 -12.712
2020-06-30 10.525 -5.499 -9.784
2020-03-31 11.043 -5.722 -10.323

XOMA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XOMA has a Quality Grade of C, ranking ahead of 61.51% of graded US stocks.
  • XOMA's asset turnover comes in at 0.252 -- ranking 175th of 677 Pharmaceutical Products stocks.
  • VBLT, SRNE, and CNCE are the stocks whose asset turnover ratios are most correlated with XOMA.

The table below shows XOMA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.252 1 0.254
2021-03-31 0.277 1 0.222
2020-12-31 0.301 1 0.242
2020-09-30 0.025 1 -0.219
2020-06-30 0.116 1 -0.137
2020-03-31 0.126 1 -0.147

XOMA Price Target

For more insight on analysts targets of XOMA, see our XOMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.67 Average Broker Recommendation 1.75 (Moderate Buy)

XOMA Stock Price Chart Interactive Chart >

Price chart for XOMA

XOMA Price/Volume Stats

Current price $24.49 52-week high $46.32
Prev. close $24.79 52-week low $18.04
Day low $24.01 Volume 12,346
Day high $24.79 Avg. volume 37,747
50-day MA $29.06 Dividend yield N/A
200-day MA $34.66 Market Cap 277.01M

XOMA Corporation (XOMA) Company Bio

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.

XOMA Latest News Stream

Event/Time News Detail
Loading, please wait...

XOMA Latest Social Stream

Loading social stream, please wait...

View Full XOMA Social Stream

Latest XOMA News From Around the Web

Below are the latest news stories about XOMA Corp that investors may wish to consider to help them evaluate XOMA as an investment opportunity.

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeuti

Yahoo | September 22, 2021

Here's What XOMA Corporation's (NASDAQ:XOMA) Shareholder Ownership Structure Looks Like

A look at the shareholders of XOMA Corporation ( NASDAQ:XOMA ) can tell us which group is most powerful. Generally...

Yahoo | September 21, 2021

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series

Yahoo | September 20, 2021

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021. The presentation will be available on demand beginning September 13, 2021, at at 7:00 AM ET and can be accessed at https://bit.ly/2X7bWb0. The presentation can also be accessed by visiting the investor relations section of the Company’s websi

Yahoo | September 13, 2021

Why Did Wedbush Downgrade Xoma?

Wedbush has cut XOMA Corporation (NASDAQ: XOMA) to neutral from outperform and lowered its price target to $22 from $41. Analyst Liana Moussatos notes that Novartis AG (NYSE: NVS) abandoned iscalimab as a kidney transplant candidate following disappointing phase 2b results. Related Content: Novartis Stops Iscalimab Trial In Kidney Transplant Patients. Novartis continues to assess iscalimab in liver transplantation in the Phase 2b CONTRAIL I study, and in Phase 2a study for Hidradenitis suppurati

Yahoo | September 7, 2021

Read More 'XOMA' Stories Here

XOMA Price Returns

1-mo -14.61%
3-mo -30.96%
6-mo -38.76%
1-year 31.03%
3-year 47.62%
5-year 135.48%
YTD -44.50%
2020 61.65%
2019 115.81%
2018 -64.47%
2017 743.60%
2016 -84.14%

Continue Researching XOMA

Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:

XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.3101 seconds.